Patent application number | Description | Published |
20080286868 | METAL BINDING COMPOUNDS AND THEIR USE IN CELL CULTURE MEDIUM COMPOSITIONS - The present invention is directed generally to metal binding compounds which may be added to cell culture media to replace factors required for cultivation of the cells (e.g. transferrin) which are of animal or human origin. More specifically, the invention is directed to metal binding compounds or complexes thereof comprising one or more transition element cations (such as ferrous or ferric ions), which are added to cell and tissue culture medium compositions. The metal binding compounds may be added to the media alone or may be first complexed with a transition metal ion. The invention is also directed to methods of use of such compositions, including, for example, methods for the cultivation of eukaryotic cells, particularly animal cells, in vitro. The invention also relates to compositions comprising such culture media and one or more cells, and to kits comprising one or more of the above-described compositions. The compositions of the present invention obviate the need for naturally derived metal-binding proteins, such as transferrin and ceruloplasmin, which may contain blood-borne pathogens. | 11-20-2008 |
20090280532 | SERUM-FREE MAMMALIAN CELL CULTURE MEDIUM, AND USES THEREOF - The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells. | 11-12-2009 |
20090280533 | SERUM-FREE MAMMALIAN CELL CULTURE MEDIUM, AND USES THEREOF - The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells. | 11-12-2009 |
20110183375 | METAL BINDING COMPOUNDS AND THEIR USE IN CELL CULTURE MEDIUM COMPOSITIONS - The present invention is directed generally to metal binding compounds which may be added to cell culture media to replace factors required for cultivation of the cells (e.g. transferrin) which are of animal or human origin. More specifically, the invention is directed to metal binding compounds or complexes thereof comprising one or more transition element cations (such as ferrous or ferric ions), which are added to cell and tissue culture medium compositions. The metal binding compounds may be added to the media alone or may be first complexed with a transition metal ion. The invention is also directed to methods of use of such compositions, including, for example, methods for the cultivation of eukaryotic cells, particularly animal cells, in vitro. The invention also relates to compositions comprising such culture media and one or more cells, and to kits comprising one or more of the above-described compositions. The compositions of the present invention obviate the need for naturally derived metal-binding proteins, such as transferrin and ceruloplasmin, which may contain blood-borne pathogens. | 07-28-2011 |
20130065275 | SERUM-FREE MAMMALIAN CELL CULTURE MEDIUM, AND USES THEREOF - The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells. | 03-14-2013 |
Patent application number | Description | Published |
20090263397 | Combination anti-cancer therapy - The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula (I) (e.g. OSI-906). Examples of such anti-cancer agents or treatments include doxorubicin, cisplatin, and ionizing radiation. The present invention also provides a pharmaceutical composition comprising an anti-cancer agent that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula (I), in a pharmaceutically acceptable carrier. The present invention also provides a method of identifying tumor cells that will respond most favorably to treatment with a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor. | 10-22-2009 |
20110275644 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS - The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor that inhibits both IGF-1R and IR kinases. Methods are provided for identifying patients with cancer who are likely to benefit from treatment with an IGF-1R kinase inhibitor that inhibits both IGF-1R and IR kinases. Methods are also provided for identifying patients with cancer who are likely to benefit from treatment with an IGF-1R kinase inhibitor that inhibits both IGF-1R and IR kinases, but who would likely not respond to therapy with an anti-IGF-1R antibody. Methods are also provided for identifying patients with cancer who are more likely to benefit from treatment with anti-IGF-1R antibody. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate these methods are also provided. | 11-10-2011 |
20120220595 | Deuterated Tyrosine Kinase Inhibitors - Compounds of Formula I, as shown below and defined herein: enriched in deuterium, and pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by IGF-1R and/or IR. | 08-30-2012 |
20130005733 | COMBINATION ANTI-CANCER THERAPY - Methods and compositions for treating cancer comprising administering to a patient inhibitors of mT0RC1/C2, IGF-1 R, and IR. In some aspects, a combination of an mT0RC1/C2 inhibitor and an IGF-1 R/IR inhibitor is employed. Other aspects are described herein. | 01-03-2013 |
Patent application number | Description | Published |
20080234354 | Methods And Compositions For Controlling Body Weight And Appetite - The present invention provides novel compositions and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound. The invention also provides novel compositions and methods for treating or preventing disorders related to or complicated by excessive body weight or obesity, including coronary heart disease, osteoarthritis, osteoporosis, dislipidemias, gout, atherosclerosis, joint pain, sexual and fertility problems, respiratory problems, gall bladder disease, skin conditions, hypertension, diabetes, stroke, pulmonary embolism, sleep apnea, idiopathic intracranial hypertension, lower extremity venous stasis disease, gastro-esophageal reflux, urinary stress incontinence, metabolic syndrome, insulin resistance and cancer. The methods and compositions of the invention may employ a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound alone, or in combination with a second anti-appetite or anti-obesity agent. | 09-25-2008 |
20120302619 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders - The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety. | 11-29-2012 |
20130345439 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders - The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety. | 12-26-2013 |
20150148399 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders - The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety. | 05-28-2015 |
Patent application number | Description | Published |
20140200876 | BOOTSTRAPPING NAMED ENTITY CANONICALIZERS FROM ENGLISH USING ALIGNMENT MODELS - Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for training recognition canonical representations corresponding to named-entity phrases in a second natural language based on translating a set of allowable expressions with canonical representations from a first natural language, which may be generated by expanding a context-free grammar for the allowable expressions for the first natural language. | 07-17-2014 |
20150279360 | LANGUAGE MODELING IN SPEECH RECOGNITION - Some implementations include a computer-implemented method. The method can include providing a training set of text samples to a semantic parser that associates text samples with actions. The method can include obtaining, for each of one or more of the text samples of the training set, data that indicates one or more domains that the semantic parser has associated with the text sample. For each of one or more domains, a subset of the text samples of the training set can be generated that the semantic parser has associated with the domain. Using the subset of text samples associated with the domain, a language model can be generated for one or more of the domain. Speech recognition can be performed on an utterance using the one or more language models that are generated for the one or more of the domains. | 10-01-2015 |
20150287410 | SPEECH AND SEMANTIC PARSING FOR CONTENT SELECTION - Systems, apparatus and method for speech and semantic parsing for content selection. In an aspect, a method includes selecting, for each of a plurality of voice query analyzers, an analyzer output parameter; generating a voice query model for voice queries, the voice query model including analysis fields, wherein each analysis field in at least a first portion of the analysis fields corresponds to a corresponding analyzer output parameter; receiving, from a plurality of content item providers, voice query selection data that describes analyzer output parameter values for the voice query model that satisfy selection criteria for the content item provider; and persisting the voice query selection data for the content item providers to a computer memory device; wherein the voice query analyzers include a semantic analyzer and a biometric analyzer. | 10-08-2015 |
20150309987 | Classification of Offensive Words - A computer-implemented method can include identifying a first set of text samples that include a particular potentially offensive term. Labels can be obtained for the first set of text samples that indicate whether the particular potentially offensive term is used in an offensive manner. A classifier can be trained based at least on the first set of text samples and the labels, the classifier being configured to use one or more signals associated with a text sample to generate a label that indicates whether a potentially offensive term in the text sample is used in an offensive manner in the text sample. The method can further include providing, to the classifier, a first text sample that includes the particular potentially offensive term, and in response, obtaining, from the classifier, a label that indicates whether the particular potentially offensive term is used in an offensive manner in the first text sample. | 10-29-2015 |
20150348541 | Generating Language Models - Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for generating language models. In some implementations, data is accessed that indicates a set of classes corresponding to a concept. A first language model is generated in which a first class represents the concept. A second language model is generated in which second classes represent the concept. Output of the first language model and the second language model is obtained, and the outputs are evaluated. A class from the set of classes is selected based on evaluating the output of the first language model and the output of the second language model. In some implementations, the first class and the second class are selected from a parse tree or other data that indicates relationships among the classes in the set of classes. | 12-03-2015 |
20160062985 | Clustering Classes in Language Modeling - This document describes, among other things, a computer-implemented method. The method can include obtaining a plurality of text samples that each include one or more terms belonging to a first class of terms. The plurality of text samples can be classified into a plurality of groups of text samples. Each group of text samples can correspond to a different sub-class of terms. For each of the groups of text samples, a sub-class context model can be generated based on the text samples in the respective group of text samples. Particular ones of the sub-class context models that are determined to be similar can be merged to generate a hierarchical set of context models. Further, the method can include selecting particular ones of the context models and generating a class-based language model based on the selected context models. | 03-03-2016 |
Patent application number | Description | Published |
20080256261 | Proximity Detection Method - The invention relates to a method of determining a proximity between a root node ( | 10-16-2008 |
20090003605 | TEMPORAL PROXIMITY TO VERIFY PHYSICAL PROXIMITY - A security system assesses the response time to requests for information to determine whether the responding system is in physical proximity to the requesting system. Generally, physical proximity corresponds to temporal proximity. If the response time indicates a substantial or abnormal lag between request and response, the system assumes that the lag is caused by the request and response having to travel a substantial or abnormal physical distance, or caused by the request being processed to generate a response, rather than being answered by an existing response in the physical possession of a user. If a substantial or abnormal lag is detected, the system is configured to limit subsequent access to protected material by the current user, and/or to notify security personnel of the abnormal response lag. | 01-01-2009 |
20130103947 | TEMPORAL PROXIMITY TO VERIFY PHYSICAL PROXIMITY - A security system assesses the response time to requests for information to determine whether the responding system is in physical proximity to the requesting system. Generally, physical proximity corresponds to temporal proximity. If the response time indicates a substantial or abnormal lag between request and response, the system assumes that the lag is caused by the request and response having to travel a substantial or abnormal physical distance, or caused by the request being processed to generate a response, rather than being answered by an existing response in the physical possession of a user. If a substantial or abnormal lag is detected, for example due to the fact that the information was downloaded from the Internet, the system is configured to limit subsequent access to protected material by the current user, and/or to notify security personnel of the abnormal response lag. | 04-25-2013 |